Chronic Venous ULcer TReatment Analyzing Bio-Electrical Stimulation Therapy
NCT ID: NCT00678847
Last Updated: 2008-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
50 participants
INTERVENTIONAL
2008-03-31
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary Objective:
• To evaluate the efficacy of bio-electrical stimulation therapy in the healing of chronic venous leg ulcers
Secondary Objective(s):
* To evaluate the percentage of wound healing every two weeks
* To evaluate the complete ulcer healing every two weeks
* To evaluate the time to complete ulcer healing
* To evaluate the recurrence rate at the end of the follow-up period
* To evaluate pain
* To evaluate the quality of life
Study Design and Treatment Scheme:
This is a Kingfisher Healthcare NV sponsored, national, multicenter, randomized, prospective study in which data will be collected of subjects with chronic venous leg ulcers receiving standardized conventional therapy (SCT). Subjects will be randomized into two groups receiving SCT + placebo or SCT + bio-electrical stimulation therapy (BEST) to evaluate the effect of BEST on the wound healing process.
Patients answering the eligibility criteria will receive standardized conventional therapy during 4 weeks before actual study start and will then again be evaluated on eligibility according to wound healing rate. Only patients with a wound surface that has not significantly changed (both increased or decreased) will be randomized in the treatment period.
During the treatment period patients will receive SCT with placebo or SCT in combination with bio-electrical stimulation therapy on a daily basis for two hours, during 8 weeks.
Patients will be in follow-up period for a maximum of 8 weeks after treatment period.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
B
KFH NOVO (inactive) + SCT
inactive device (placebo) 2 x 1hour/day for total period of 8 weeks + standardized conventional therapy (SCT)
A
KFH Novo (BEST) + SCT
2 x 1 hour/day bio-electrical stimulation (BEST) for total period for total period of 8 weeks in combination with standardized conventional therapy (SCT)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KFH NOVO (inactive) + SCT
inactive device (placebo) 2 x 1hour/day for total period of 8 weeks + standardized conventional therapy (SCT)
KFH Novo (BEST) + SCT
2 x 1 hour/day bio-electrical stimulation (BEST) for total period for total period of 8 weeks in combination with standardized conventional therapy (SCT)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Before any subject data is collected, the appropriate written informed consent must be obtained (see appendix H).
* Confirmation of venous insufficiency during the last 5 years by Duplex examination
* Chronic venous leg ulcers (\>12 weeks) not healing with conventional therapy
* Study ulcer size between 8 to 20 cm² and without clinical signs of infection
* No presence of other ulcers in a radius of 5 cm around the study ulcer
* No surgery for venous insufficiency within the last 6 months
* No arterial insufficiency (ABI between 0,7 and 1,3)
* BMI \< 40
* No uncontrolled diabetes or any uncontrolled systemic condition that might impair wound healing
* No decubitus wounds
* Ambulant subject
* Written informed consent
Exclusion Criteria
* Subjects having a concurrent malignancy or being less than 3 years after the end of their cancer therapy
* Subjects with active osteomyelitis
* Pregnant or breast-feeding women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kingfisher Healthcare
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kingfisher Healthcare
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mieke Flour, MD
Role: STUDY_CHAIR
UZ Gasthuisberg, Leuven (Belgium)
Michel de la Brassinne, MD
Role: PRINCIPAL_INVESTIGATOR
CHU Sart Tilman, Liege (Belgium)
Bert Boyden, MD
Role: PRINCIPAL_INVESTIGATOR
Virga Jesse Ziekenhuis, Hasselt (Belgium)
Hilde Beele, MD
Role: PRINCIPAL_INVESTIGATOR
UZ Gent, Belgium
Diane Roseeuw, MD
Role: PRINCIPAL_INVESTIGATOR
UZ Brussel (Belgium)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UZ Gasthuisberg
Leuven, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mieke Flour, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ULTRA-BEST
Identifier Type: -
Identifier Source: org_study_id